A groundbreaking step in HIV prevention has arrived. The U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) — the first and only long-acting injectable PrEP administered twice a year — for use in adults and adolescents weighing at least 35kg (77 lbs). Backed by clinical success and designed for convenience, this innovative option is changing how we approach HIV prevention. What Is Yeztugo® (lenacapavir)? Yeztugo® is a twice-a-year injectable form of p

In Brooklyn and beyond, men are taking charge of their sexual health like never before—and PrEP is leading the revolution.  Whether...

HIV is a virus that affects millions of people around the world. Over the years, various methods have emerged to prevent the transmission...